187 related articles for article (PubMed ID: 23461448)
1. [Desensitization to lenalidomide].
Cañamares Orbis I; García Muñoz C; Cortijo Cascajares S; Méndez Esteban ME
Farm Hosp; 2012; 36(6):542-3. PubMed ID: 23461448
[No Abstract] [Full Text] [Related]
2. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
3. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Seki JT; Banglawala S; Lentz EM; Reece DE
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
[No Abstract] [Full Text] [Related]
4. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Dasanu CA; Bockorny B; Alexandrescu DT
J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness.
Paumgartten FJ
Cad Saude Publica; 2014 Apr; 30(4):684-6. PubMed ID: 24896044
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
[No Abstract] [Full Text] [Related]
7. [Thalidomide for the treatment of refractory multiple myeloma].
Kakimoto T; Hattori Y; Okamoto S
Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
[No Abstract] [Full Text] [Related]
8. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
[TBL] [Abstract][Full Text] [Related]
10. Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone.
Montagnese F; Portaro S; Musumeci O; Migliorato A; Moggio M; Fagiolari G; Rodolico C
Muscle Nerve; 2015 Jun; 51(6):934-5. PubMed ID: 25524603
[No Abstract] [Full Text] [Related]
11. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.
Briani C; Torre CD; Campagnolo M; Lucchetta M; Berno T; Candiotto L; Padua L; Ermani M; Cavaletti G; Zambello R
J Peripher Nerv Syst; 2013 Mar; 18(1):19-24. PubMed ID: 23521639
[TBL] [Abstract][Full Text] [Related]
12. [Antimyeloma drugs].
Fukuhara N
Nihon Rinsho; 2015 Feb; 73 Suppl 2():195-7. PubMed ID: 25831751
[No Abstract] [Full Text] [Related]
13. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Sriskandarajah P; Pawlyn C; Mohammed K; Dearden CE; Davies FE; Morgan GJ; Boyd KD; Kaiser MF
Leuk Lymphoma; 2017 Feb; 58(2):494-497. PubMed ID: 27439571
[No Abstract] [Full Text] [Related]
14. Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
Pitini V; Arrigo C; Aloi G; Azzarello D; La Gattuta G
Haematologica; 2002 Feb; 87(2):ELT07. PubMed ID: 11836184
[No Abstract] [Full Text] [Related]
15. [Thalidomide and others: new treatment for myeloma].
Malphettes M; Fermand JP
Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
[No Abstract] [Full Text] [Related]
16. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941
[No Abstract] [Full Text] [Related]
17. Thalidomide and thrombosis.
Mehta P
Clin Adv Hematol Oncol; 2003 Aug; 1(8):464-5. PubMed ID: 16258433
[No Abstract] [Full Text] [Related]
18. Successful desensitization in a patient with lenalidomide hypersensitivity.
Phillips J; Kujawa J; Davis-Lorton M; Hindenburg A
Am J Hematol; 2007 Nov; 82(11):1030. PubMed ID: 17617781
[No Abstract] [Full Text] [Related]
19. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
